Mounjaro vs Trulicity: Titration Speed and Tolerability Compared

What Are Mounjaro and Trulicity, and How Do They Work?

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are both injectable medications used for type 2 diabetes, but they work through different receptor pathways, which explains why their clinical performance gaps are so wide. Understanding the mechanism first makes the titration and tolerability data easier to interpret.

Tirzepatide: A Dual-Receptor Agonist

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. FDA prescribing information describes the drug as a "dual GIP and GLP-1 receptor agonist" that reduces fasting and postprandial glucose while also suppressing appetite through central nervous system pathways. The GIP component appears to reduce nausea relative to GLP-1-only agonists at equivalent glucose-lowering doses, though head-to-head nausea data between tirzepatide and dulaglutide come primarily from the SURPASS program.

Dulaglutide: A GLP-1 Receptor Agonist

Dulaglutide is a GLP-1 receptor agonist fused to a human IgG4-Fc antibody fragment, giving it a half-life of approximately 5 days and enabling once-weekly dosing. It was approved by the FDA in September 2014 and has a well-characterized tolerability record spanning over a decade of real-world use. Prescribing information notes that its mechanism is selective for the GLP-1 receptor with no GIP activity.

Titration Schedules Side by Side

Both drugs require gradual dose escalation to minimize GI adverse events, but the number of titration steps and the time required to reach the maintenance dose are different. Slower titration reduces early dropout from nausea.

Mounjaro Titration Steps

The FDA-approved Mounjaro titration schedule is:

| Week | Dose | |------|------| | 1 to 4 | 2.5 mg/week (starting dose only, not therapeutic) | | 5 to 8 | 5 mg/week (first therapeutic dose) | | 9 to 12 | 7.5 mg/week (if additional glycemic control needed) | | 13 to 16 | 10 mg/week | | 17 to 20 | 12.5 mg/week | | 21+ | 15 mg/week (maximum dose) |

Reaching 15 mg requires at minimum 20 weeks (5 months) of consistent dosing. Many patients remain on 5 to 10 mg/week long-term if glycemic goals are met earlier, so not every patient completes the full 6-step escalation.

Trulicity Titration Steps

| Week | Dose | |------|------| | 1 to 4 | 0.75 mg/week (starting dose) | | 5+ | 1.5 mg/week (standard maintenance) | | After 4 weeks at 1.5 mg | 3.0 mg/week (optional escalation) | | After 4 weeks at 3.0 mg | 4.5 mg/week (maximum dose) |

Reaching 4.5 mg takes a minimum of 12 weeks. Most patients in clinical practice and in the REWIND trial pubmed.ncbi.nlm.nih.gov/31189511/ were maintained at 1.5 mg/week, which was the only dose available during that trial's enrollment period.

Key Titration Differences

Mounjaro has six dose steps; Trulicity has four. Mounjaro's first step (2.5 mg) is explicitly labeled a "starting" dose with no independent therapeutic claim, functioning purely as a tolerability ramp. Trulicity's 0.75 mg starting dose is also sub-therapeutic for most patients but still provides measurable HbA1c reduction compared with placebo.

Patients who cannot tolerate dose escalation at 4-week intervals can remain at the previous dose for an additional 4 weeks on both medications, per FDA labeling. Dose reductions are permitted for both agents.

GI Tolerability: Nausea, Diarrhea, and Vomiting Rates

GI side effects are the primary reason patients discontinue or refuse to escalate either drug. Comparing absolute rates between trials is imperfect because study populations, background medications, and titration protocols differ.

Nausea Rates

In SURPASS-2 (N=1,879), which compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes, nausea was reported in 17 to 22% of tirzepatide-treated patients versus 18% in the semaglutide group pubmed.ncbi.nlm.nih.gov/34170647/. Dulaglutide trials historically report nausea rates of 12 to 20% depending on dose, with the highest rates seen at 4.5 mg.

Because SURPASS-2 used semaglutide as comparator rather than dulaglutide, direct head-to-head nausea rates between tirzepatide and dulaglutide are not available from a single trial. Cross-trial comparison suggests comparable early nausea at lower doses, with tirzepatide showing slightly higher rates at the 15 mg dose relative to dulaglutide 4.5 mg.

Vomiting and Diarrhea

SURPASS-2 reported vomiting in 6 to 9% of tirzepatide patients across doses. In AWARD-5 (N=1,098), which evaluated dulaglutide 0.75 mg and 1.5 mg versus sitagliptin, vomiting occurred in approximately 6 to 7% of the 1.5 mg group pubmed.ncbi.nlm.nih.gov/24742492/.

Diarrhea rates in SURPASS-2 were 12 to 14% for tirzepatide versus 12% for semaglutide. Dulaglutide's prescribing information lists diarrhea in approximately 12% of patients at 1.5 mg. These figures are broadly similar between the two drugs.

Discontinuation Due to GI Events

In SURPASS-2, GI-related discontinuations were 4.3% for tirzepatide 5 mg, 5.2% for tirzepatide 10 mg, and 7.4% for tirzepatide 15 mg. The prescribing information for dulaglutide reports GI discontinuation rates of approximately 5.4% at 1.5 mg. Tirzepatide at the 15 mg dose carries a modestly higher dropout rate than dulaglutide at its standard dose, but the comparison is confounded by dose magnitude and the more aggressive glycemic and weight targets tirzepatide patients typically pursue.

HbA1c Reduction: What the Trials Show

Glycemic efficacy is the primary reason a clinician prescribes either drug, so this comparison deserves careful unpacking of the trial data.

SURPASS-2 Tirzepatide Results

SURPASS-2 (N=1,879; 40 weeks) found mean HbA1c reductions of 2.01% for tirzepatide 5 mg, 2.24% for tirzepatide 10 mg, and 2.30% for tirzepatide 15 mg, all measured from a mean baseline HbA1c of approximately 8.3% pubmed.ncbi.nlm.nih.gov/34170647/. All three tirzepatide doses were statistically superior to semaglutide 1 mg (P<0.001), which produced a 1.86% reduction.

The proportion of patients reaching an HbA1c below 7.0% was 82 to 92% across tirzepatide doses versus 79% for semaglutide 1 mg.

REWIND Dulaglutide Results

REWIND (N=9,901; median 5.4 years; dulaglutide 1.5 mg) was primarily a cardiovascular outcomes trial, but it reported a mean HbA1c reduction of 0.96% from a baseline of 7.3% pubmed.ncbi.nlm.nih.gov/31189511/. The lower baseline HbA1c in REWIND versus SURPASS-2 explains some of the difference, as regression to the mean is smaller when baseline is closer to target.

The AWARD program trials with baseline HbA1c of 8.0 to 8.4% reported dulaglutide 1.5 mg reductions of approximately 1.4 to 1.6%, still substantially below tirzepatide's 2.01 to 2.30% range.

Clinical Takeaway on HbA1c

At comparable titration timelines and in patients with similar baseline HbA1c levels around 8.0 to 8.5%, tirzepatide produces roughly 0.5 to 0.9% greater HbA1c reduction than dulaglutide 1.5 mg. This difference is clinically meaningful given that a 0.5% HbA1c reduction is associated with measurable reductions in microvascular complication risk pubmed.ncbi.nlm.nih.gov/12829596/.

Weight Loss: Where the Gap Is Largest

The weight-loss difference between these two drugs is substantial and reflects tirzepatide's dual mechanism, particularly the GIP component's effect on adipose tissue and central appetite regulation.

Body Weight in SURPASS-2

SURPASS-2 reported mean weight changes of minus 7.8 kg (17.2 lb) for tirzepatide 5 mg, minus 9.3 kg (20.5 lb) for 10 mg, and minus 11.2 kg (24.7 lb) for 15 mg over 40 weeks pubmed.ncbi.nlm.nih.gov/34170647/.

Body Weight With Dulaglutide

REWIND's cardiovascular primary outcome overshadowed its weight data, but the trial reported a modest mean weight reduction of approximately 1.5 kg (3.3 lb) from a baseline of roughly 89 kg over the first year at 1.5 mg. AWARD trials showed weight reductions of 2.9 to 3.1 kg (6.4 to 6.8 lb) at 1.5 mg over 26 to 52 weeks.

Tirzepatide at 15 mg produces roughly three to four times the body weight reduction of dulaglutide 1.5 mg over a comparable period. For a patient with type 2 diabetes who also needs meaningful weight reduction, this difference may drive the prescribing decision.

Cardiovascular Outcomes Evidence

Cardiovascular safety and benefit data shape prescribing for patients with established cardiovascular disease or high cardiovascular risk.

REWIND and Dulaglutide's CV Evidence

REWIND (N=9,901; median 5.4 years) found that dulaglutide 1.5 mg reduced the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 12% compared with placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) pubmed.ncbi.nlm.nih.gov/31189511/. The Lancet published this as a dedicated cardiovascular outcomes trial, giving dulaglutide a formal cardiovascular benefit label from the FDA.

SURPASS-CVOT and Tirzepatide

The SURPASS-CVOT trial (N=12,500+) comparing tirzepatide against insulin glargine in high-cardiovascular-risk patients with type 2 diabetes was ongoing as of this article's review date. Tirzepatide does not yet carry an FDA-approved cardiovascular risk-reduction indication for type 2 diabetes, though a separate SURMOUNT-MMO cardiovascular outcomes trial is evaluating tirzepatide for obesity-related cardiovascular endpoints [clinicaltrials.gov identifier NCT05556512].

For patients with established atherosclerotic cardiovascular disease who need a proven CV outcome benefit, dulaglutide's REWIND data currently provide a regulatory-supported advantage over tirzepatide in this specific context.

Switching from Mounjaro to Trulicity (or Vice Versa)

Patients and clinicians consider switching for several reasons: cost and insurance coverage, intolerable side effects at higher tirzepatide doses, or inadequate glycemic response to dulaglutide.

When Switching from Mounjaro to Trulicity Makes Sense

Switching from tirzepatide to dulaglutide may be appropriate when:

• Cost or formulary access makes tirzepatide unsustainable long-term.
• A patient achieves target HbA1c on tirzepatide but needs a medication with a proven dedicated cardiovascular outcomes trial result.
• GI side effects on tirzepatide 10 to 15 mg are persistent despite multiple dose-reduction attempts.

When switching, most clinicians start dulaglutide at 0.75 mg/week regardless of the tirzepatide dose being discontinued, because receptor pharmacology differs and prior exposure to one GLP-1 agonist does not eliminate the titration requirement for another. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends re-titration from the starting dose when switching between GLP-1-containing therapies aace.com.

There is no established washout period required before switching from tirzepatide to dulaglutide, given their once-weekly dosing and comparable half-lives (tirzepatide approximately 5 days; dulaglutide approximately 5 days). The switch can occur the week after the last tirzepatide injection.

When Switching from Trulicity to Mounjaro Makes Sense

This is the more common direction in current clinical practice, driven by greater glycemic and weight efficacy data for tirzepatide. Switching is reasonable when:

• HbA1c remains above 7.0% on maximally tolerated dulaglutide.
• The patient's weight loss goal is not met at 4.5 mg dulaglutide.
• Insurance coverage for tirzepatide becomes available.

Clinicians should re-titrate tirzepatide from 2.5 mg/week when switching from any other GLP-1 agent. Prior GLP-1 exposure does not guarantee tolerability at tirzepatide's higher doses.

A Practical Decision Framework for the Tirzepatide/Dulaglutide Switch

Use the four factors below to guide the switch direction:

| Factor | Favors Tirzepatide | Favors Dulaglutide | |--------|---------------------|---------------------| | HbA1c above goal on maximum tolerated GLP-1 | Yes | No | | Weight loss >5% needed | Yes | No | | Established ASCVD needing proven CVOT benefit | No | Yes | | Cost constraint or formulary restriction | No | Yes |

Injection Device and Patient Experience

Both drugs are delivered via a single-use, prefilled auto-injector pen that can be administered in the abdomen, thigh, or upper arm. Neither requires manual needle attachment, and neither requires refrigeration for short-term storage (both can be kept at room temperature up to 77 degrees Fahrenheit for up to 14 days for tirzepatide or 14 days for dulaglutide).

Injection volume differs. Tirzepatide uses a 0.5 mL fixed-volume injection across all doses. Dulaglutide uses a 0.5 mL injection for 0.75 mg and 1.5 mg doses, and a 0.5 mL single-dose pen for the 3.0 mg and 4.5 mg doses as well. Patients switching between the two drugs generally find the device experience comparable, which reduces one barrier to adherence during the transition.

Drug Interactions, Contraindications, and Special Populations

Both agents share a contraindication for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2, based on rodent data showing thyroid C-cell tumors at supratherapeutic doses pubmed.ncbi.nlm.nih.gov/20103774/. Neither is approved for use in pregnancy, and both should be discontinued at least 2 months before a planned pregnancy attempt per current endocrinology guidance.

Renal impairment does not require dose adjustment for either drug based on current FDA labeling, though GI side effects may be more pronounced in patients with chronic kidney disease stage 3 and above due to altered drug clearance dynamics. Hepatic impairment has limited data for both agents; clinical use proceeds with monitoring rather than formal dose reduction.

Oral medications with narrow therapeutic windows (warfarin, cyclosporine) may require monitoring because both drugs slow gastric emptying, which can alter the absorption rate of concomitant oral agents.

Approved Indications: How They Differ

Tirzepatide holds FDA approval for type 2 diabetes (May 2022) and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity under the brand name Zepbound (November 2023) fda.gov. Dulaglutide is approved for type 2 diabetes (September 2014) and, since 2020, for reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

This means a physician treating a patient with type 2 diabetes plus established cardiovascular disease plus obesity may favor tirzepatide for its obesity approval and glycemic potency while noting that only dulaglutide currently carries a dedicated CV risk-reduction label for the type 2 diabetes population.

Cost and Insurance Access

As of early 2025, the list price of Mounjaro is approximately $1,069 per month for a 4-pen carton without insurance. Trulicity's list price is approximately $878 per month for a 4-pen carton. Both manufacturers offer savings programs: Eli Lilly (which makes both drugs) offers the Lilly Insulin Value Program and separate manufacturer coupons that can reduce cost to $25, $150 per month for commercially insured patients.

Medicare Part D coverage for tirzepatide as a diabetes medication became available in 2023 and varies by plan. Coverage for tirzepatide as an obesity medication (Zepbound) under Medicare Part D became possible after the Treat and Reduce Obesity Act provisions, though plan inclusion remains inconsistent as of this writing.

Summary Comparison Table

| Parameter | Tirzepatide (Mounjaro) | Dulaglutide (Trulicity) | |---|---|---| | Mechanism | Dual GIP/GLP-1 | GLP-1 only | | Starting dose | 2.5 mg/week | 0.75 mg/week | | Max dose | 15 mg/week | 4.5 mg/week | | Titration steps | 6 | 4 | | Time to max dose | 20+ weeks | 12+ weeks | | HbA1c reduction (trial) | 2.01 to 2.30% (SURPASS-2) | 0.96 to 1.6% (REWIND/AWARD) | | Weight loss | 7.8 to 11.2 kg (SURPASS-2) | 1.5 to 3.1 kg (REWIND/AWARD) | | CV outcome trial | Pending (SURPASS-CVOT) | Positive (REWIND, HR 0.88) | | GI discontinuation | 4.3 to 7.4% (dose-dependent) | ~5.4% at 1.5 mg | | Obesity indication | Yes (as Zepbound) | No | | List price/month | ~$1,069 | ~$878 |